Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Bruce D ChesonInternational Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards

Abstract

An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders.

References

Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Apr 1, 1995·Leukemia Research·J M Bennett
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B QuesnelJ L Harousseau
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A CaligiuriC D Bloomfield
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Sep 20, 2002·Blood·James W VardimanRichard D Brunning

❮ Previous
Next ❯

Citations

Apr 1, 2006·Annals of Hematology·Je-Hwan LeeUNKNOWN Cooperative Study Group A for Hematology
Mar 22, 2007·Annals of Hematology·Torsten HaferlachClaudia Haferlach
Jan 29, 2011·Annals of Hematology·Alexandar TzankovUrsula Günthert
Sep 22, 2011·Annals of Hematology·Hun Ju LeeMeir Wetzler
Oct 24, 2012·Annals of Hematology·Eva LengfelderUNKNOWN German Acute Myeloid Leukemia Cooperative Group (AMLCG)
Jan 29, 2013·Annals of Hematology·Juan Carlos Hernández-BoludaUNKNOWN Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Oct 22, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Abbas H PanjuShabbir M H Alibhai
Oct 19, 2011·Current Treatment Options in Oncology·Alan K Burnett, Robert K Hills
Jul 24, 2010·Current Hematologic Malignancy Reports·Mohamed RadhiAlan Gamis
Apr 9, 2013·Current Hematologic Malignancy Reports·Karen-Sue B Carlson, Monica L Guzman
Jul 19, 2012·Current Oncology Reports·Raya Mawad, Elihu H Estey
Jan 6, 2012·International Journal of Hematology·Moshe C Ornstein, Mikkael A Sekeres
Sep 13, 2012·International Journal of Hematology·Peipei XuZuhong Lu
Nov 8, 2012·International Journal of Hematology·Brian McLaughlinMichael Boyiadzis
Feb 2, 2013·International Journal of Hematology·Yunsuk ChoiKyoo-Hyung Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.